Robert S. Busch

4.5k total citations · 3 hit papers
45 papers, 1.3k citations indexed

About

Robert S. Busch is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Robert S. Busch has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Surgery and 13 papers in Molecular Biology. Recurrent topics in Robert S. Busch's work include Diabetes Management and Research (24 papers), Diabetes Treatment and Management (23 papers) and Metabolism, Diabetes, and Cancer (11 papers). Robert S. Busch is often cited by papers focused on Diabetes Management and Research (24 papers), Diabetes Treatment and Management (23 papers) and Metabolism, Diabetes, and Cancer (11 papers). Robert S. Busch collaborates with scholars based in United States, Denmark and Canada. Robert S. Busch's co-authors include Michael P. Kane, Katherine R. Tuttle, Mark Lakshmanan, Alan G. Zimmermann, Brian Rayner, Fady T. Botros, Robert A. Hamilton, Athena Philis‐Tsimikas, Gary Bakst and Vaishali Bhosekar and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Diabetes.

In The Last Decade

Robert S. Busch

42 papers receiving 1.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

2018 460 citations Katherine R. Tuttle, Mark Lakshmanan et al. The Lancet Diabetes & Endocrinology profile →
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

2019 267 citations Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology profile →
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

2024 74 citations Johannes F.E. Mann, Peter Rossing et al. Nature Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert S. Busch	1.1k	492	391	247	112	45	1.3k
Sue Sha	1.3k 1.1×	432 0.9×	735 1.9×	166 0.7×	74 0.7×	18	1.5k
Nicole Vaccaro	619 0.6×	272 0.6×	408 1.0×	171 0.7×	48 0.4×	25	945
Anna Maria Langkilde	1.9k 1.7×	1.0k 2.1×	901 2.3×	373 1.5×	215 1.9×	21	2.1k
Gideon Bahn	937 0.8×	276 0.6×	241 0.6×	74 0.3×	91 0.8×	31	1.5k
Farshad Kajbaf	475 0.4×	398 0.8×	165 0.4×	44 0.2×	95 0.8×	24	801
Tatsuya Suzuki	270 0.2×	391 0.8×	223 0.6×	76 0.3×	75 0.7×	71	1.1k
Yinfang Tu	272 0.2×	249 0.5×	295 0.8×	125 0.5×	89 0.8×	52	957
Katsuya Yamazaki	471 0.4×	248 0.5×	197 0.5×	77 0.3×	56 0.5×	49	1.2k
David P. Sonne	783 0.7×	502 1.0×	604 1.5×	141 0.6×	16 0.1×	53	1.6k
Shadi Hamoud	406 0.4×	178 0.4×	314 0.8×	103 0.4×	22 0.2×	34	932

Countries citing papers authored by Robert S. Busch

Since Specialization

Citations

This map shows the geographic impact of Robert S. Busch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Busch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Busch more than expected).

Fields of papers citing papers by Robert S. Busch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Busch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Busch. The network helps show where Robert S. Busch may publish in the future.

Co-authorship network of co-authors of Robert S. Busch

This figure shows the co-authorship network connecting the top 25 collaborators of Robert S. Busch. A scholar is included among the top collaborators of Robert S. Busch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert S. Busch. Robert S. Busch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Le, Thu H., et al.. (2024). The role of blood testing in prevention, diagnosis, and management of chronic diseases: A review. The American Journal of the Medical Sciences. 368(4). 274–286. 11 indexed citations

DeFronzo, Ralph A., Richard J. Auchus, Irina Bancos, et al.. (2024). Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 14(7). e081121–e081121.

Mann, Johannes F.E., Peter Rossing, George L. Bakris, et al.. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature Medicine. 30(10). 2849–2856. 74 indexed citations breakdown →

Goldman, Jennifer D., Robert S. Busch, & Eden Miller. (2024). Best-Practice Perspectives on Improving Early Detection and Management of Chronic Kidney Disease Associated With Type 2 Diabetes in Primary Care. Clinical Diabetes. 42(3). 429–442. 2 indexed citations

Patel, Dhiren & Robert S. Busch. (2021). Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. Journal of Cardiovascular Pharmacology and Therapeutics. 26(6). 524–532. 4 indexed citations

Busch, Robert S., et al.. (2021). The Occurrence and Burden of Hypophosphatasia in an Ambulatory Care Endocrinology Practice. Endocrine Practice. 27(12). 1189–1192. 3 indexed citations

Zinman, Bernard, Vaishali Bhosekar, Robert S. Busch, et al.. (2019). Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 7(5). 356–367. 267 indexed citations breakdown →

Tuttle, Katherine R., Mark Lakshmanan, Brian Rayner, et al.. (2018). Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The Lancet Diabetes & Endocrinology. 6(8). 605–617. 460 indexed citations breakdown →

Webb, David J., Blai Coll, Hiddo J.L. Heerspink, et al.. (2017). Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R&D. 17(3). 441–448. 7 indexed citations

10.

Kane, Michael P., et al.. (2009). Accuracy and Precision of Four Value-Added Blood Glucose Meters: the Abbott Optium, the DDI Prodigy, the HDI True Track, and the HypoGuard Assure Pro. Diabetes Technology & Therapeutics. 11(9). 587–592. 8 indexed citations

11.

Kane, Michael P., et al.. (2008). A Glucose Meter Accuracy and Precision Comparison: The FreeStyle Flash Versus the Accu-Chek Advantage, Accu-Chek Compact Plus, Ascensia Contour, and the BD Logic. Diabetes Technology & Therapeutics. 10(2). 102–110. 40 indexed citations

12.

Kane, Michael P., et al.. (2007). Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance. Endocrine Practice. 13(1). 11–16. 44 indexed citations

13.

Baumeister, F. A. M., et al.. (2006). Glucose-Monitoring with Continuous Subcutaneous Microdialysis in Neonatal Diabetes Mellitus. Klinische Pädiatrie. 218(4). 230–232. 6 indexed citations

14.

Kane, Michael P., et al.. (2005). The Utility of Oral Diabetes Medications in Type 2 Diabetes of the Young. Current Diabetes Reviews. 1(1). 83–92. 39 indexed citations

15.

Stroup, Jeffrey S., Michael P. Kane, Robert S. Busch, Gary Bakst, & Robert A. Hamilton. (2004). The Utility of Insulin Glargine in the Treatment of Diabetes Mellitus. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(6). 736–742. 4 indexed citations

16.

Kane, Michael P., Robert S. Busch, Gary Bakst, & Robert A. Hamilton. (2004). Substitution of Pioglitazone for Troglitazone in Patients with Type 2 Diabetes. Endocrine Practice. 10(1). 18–23. 3 indexed citations

17.

Stroup, Jeffrey S., Michael P. Kane, Robert S. Busch, Gary Bakst, & Robert A. Hamilton. (2003). The Diabetes Home Visitation Program. American Journal of Pharmaceutical Education. 67(3). 91–91. 1 indexed citations

18.

Kane, Michael P., et al.. (2001). Cholesterol and Glycemic Effects of Niaspan in Patients with Type 2 Diabetes. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(12). 1473–1478. 13 indexed citations

19.

Carroll, Patricia B., Raymonde D Herskowitz, Andrew Goodman, Robert S. Busch, & Richard S. Beaser. (1992). Rapid onset of severe retinopathy, cataracts and neuropathy in young patients with diabetes mellitus. Acta Paediatrica. 81(4). 355–358. 7 indexed citations

20.

Goodman, Andrew, et al.. (1988). Effects of Prolactin and Growth Hormone on Tissue and Serum Carnitine in the Rat*. Endocrinology. 123(4). 1955–1961. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact